DNLI (DNLI) Stock Price & Analysis
DNLI (DNLI) fell 2.28% to USD 22.28 as of September 8, 2026 at 05:00 UTC, according to Nexqual real-time market data.
DNLI last closed at USD 22.28; the session ranged USD 22.15–22.48 on volume of 799,633 shares. Market capitalization is —, with a 52-week range of USD 12.58–27.3 (NMS). Source: Nexqual, September 8, 2026 at 05:00 UTC.
Key Statistics (as of September 8, 2026 at 05:00 UTC)
| Price | USD 22.28 |
|---|---|
| Change | ▼ 2.28% (down) |
| Previous Close | USD 22.28 |
| Open | USD 22.28 |
| Day Range | USD 22.15 – 22.48 |
| 52-Week Range | USD 12.58 – 27.3 |
| Volume | 799,633 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (DNLI)
Nexqual's technical model rates DNLI "SELL" based on 2 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 05:00 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 34.72 (neutral) |
| vs SMA50 | Below (USD 24.43) |
| MACD | -0.35 (negative) |
From DNLI's Latest SEC 10-K Filing (filed 2026-02-26)
Source: SEC EDGAR 10-K. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ALEC | Alector, Inc. | USD 2.46 | ▼ 9.56% |
| ARVN | Arvinas, Inc. | USD 9.39 | ▼ 2.09% |
| RARE | Ultragenyx Pharmaceutical Inc. | USD 15.3 | ▼ 42.33% |
| BBIO | BridgeBio Pharma, Inc. | USD 74.84 | ▼ 2.17% |
| RCUS | Arcus Biosciences, Inc. | USD 29.66 | ▼ 0.64% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:00 UTC. This page is informational and not investment advice.